Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Loteprednol etabonate
Drug ID BADD_D01324
Description Loteprednol Etabonate (LE) is a topical corticoid anti-inflammatory. It is used in ophthalmic solution for the treatment of steroid responsive inflammatory conditions of the eye such as allergic conjunctivitis, uveitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, and selected infective conjunctivitides. As a nasal spray, it can be used for the treatment and management of seasonal allergic rhinitis. Most prescription LE products, however, tend to be indicated for the treatment of post-operative inflammation and pain following ocular surgery [FDA Label]. A number of such new formulations that have been approved include Kala Pharmaceutical's Inveltys - the first twice-daily (BID) ocular corticosteroid approved for this indication, designed specifically to enhance patient compliance and simplified dosing compared to all other similar ocular steroids that are dosed four times daily [L4545]. Moreover, LE was purposefully engineered to be a 'soft drug', one that is designed to be active locally at the site of administration and then rapidly metabolized to inactive components after eliciting its actions at the desired location, thereby subsequently minimizing the chance for adverse effects [A38693].
Indications and Usage As an ophthalmic it is used for the treatment of steroid responsive inflammatory conditions of the eye such as allergic conjunctivitis, uveitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, and selected infective conjunctivitides. As a nasal spray, used for the treatment and management of seasonal allergic rhinitis.
Marketing Status Prescription; Discontinued
ATC Code S01BA14
DrugBank ID DB14596
KEGG ID D01689
MeSH ID D000069559
PubChem ID 444025
TTD Drug ID D0X6GN
NDC Product Code 55718-152; 71571-333; 46439-8744; 63190-0780; 46439-8743; 24208-353; 81861-0027; 55718-142; 68682-299; 60269-287; 65089-0037; 63190-0220; 17478-830; 11014-0439; 50383-265; 71571-121; 24208-503; 55718-153; 15308-0722; 55718-154; 55718-155; 24208-443; 81861-0028; 24208-299; 24208-507; 24208-508; 62756-232
Synonyms Loteprednol Etabonate | Etabonate, Loteprednol | CEHOAC | Chloromethyl 17-ethoxycarbonyloxy-11-hydroxy-3-oxoandrosta-1,4-diene-17-carboxylate | 17-ethoxycarbonyloxy-11-hydroxy-3-oxoandrosta-1,4-diene-17-carboxylate, Chloromethyl | Chloromethyl 17 ethoxycarbonyloxy 11 hydroxy 3 oxoandrosta 1,4 diene 17 carboxylate | Lotemax | Loteprednol | Alrex
Chemical Information
Molecular Formula C24H31ClO7
CAS Registry Number 82034-46-6
SMILES CCOC(=O)OC1(CCC2C1(CC(C3C2CCC4=CC(=O)C=CC34C)O)C)C(=O)OCCl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Vision blurred17.17.01.010; 06.02.06.0070.001645%
Visual acuity reduced17.17.01.011; 06.02.03.001--
Visual field defect17.17.01.001; 06.02.07.003--Not Available
Visual impairment06.02.06.0080.001097%Not Available
Conjunctival hyperaemia06.04.01.004--Not Available
Eyelid margin crusting23.03.03.029; 06.04.04.0050.001097%Not Available
Eye pruritus06.04.05.0060.001097%Not Available
Ocular discomfort06.08.03.0080.001097%Not Available
Nerve injury17.02.10.007; 12.01.12.002--Not Available
Injection25.01.02.011--Not Available
Corneal thinning06.06.03.009--Not Available
Scleral thinning06.09.06.004--Not Available
Anterior chamber inflammation06.04.10.002--Not Available
Inflammation08.01.05.0070.001097%Not Available
Conjunctival disorder06.06.02.004--Not Available
Corneal disorder06.08.01.004--Not Available
Sensation of foreign body08.01.09.002--Not Available
The 2th Page    First    Pre   2    Total 2 Pages